Ejaz Mahmood, MD
Endocrinology, Diabetes & Metabolism · Milford, DENPI 1366895500
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novo Nordisk at 25.4% of the total. Reporting peaked in 2021 at $868 and has fallen 80.7% since, to $167 in 2025.
Across 68 payments — averaging $31.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$540
- AstraZeneca$383
- Medtronic$288
- Lilly USA, LLC$274
- Abbott$206
- Amgen$66
- plus $366 from 11 others
What the payments were for
- Food & beverage$2,11199%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $540 |
| AstraZeneca | 4 | $383 |
| Medtronic | 7 | $288 |
| Lilly USA, LLC | 13 | $274 |
| Abbott | 10 | $206 |
| Amgen | 3 | $66 |
| Radius Health, Inc. | 2 | $63 |
| Merck | 4 | $54 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Dexcom, Inc. | 2 | $37 |
| Sequel Med Tech, LLC | 2 | $36 |
| Mannkind Corporation | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Insulet Corporation | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,123 in reported general payments places this provider in the 65th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
See all endocrinology, diabetes & metabolism providers in Delaware →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 291 | $482,051 |
| JardianceEmpagliflozin | 204 | $280,708 |
| TrulicityDulaglutide | 131 | $184,454 |
| MounjaroTirzepatide | 137 | $168,588 |
| JanuviaSitagliptin Phosphate | 122 | $124,715 |
| RybelsusSemaglutide | 47 | $96,240 |
| Tresiba Flextouch U-200Insulin Degludec | 82 | $78,397 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 54 | $61,754 |
| FarxigaDapagliflozin Propanediol | 56 | $59,927 |
| Humalog Kwikpen U-200Insulin Lispro | 47 | $55,574 |
| Tresiba Flextouch U-100Insulin Degludec | 61 | $45,688 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 56 | $39,779 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $31,208 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $27,744 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $27,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $540 | $581,017349 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Baqsimi | $274 | $371,485301 claims |
| MerckJanuvia | $54 | $124,715122 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $14 | $61,75454 claims |
| AstraZenecaFarxiga | $383 | $59,92756 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
Other endocrinology, diabetes & metabolism in Milford
- Nira MadisiMilford$23K
- Lei Lei MinMilford$366
- Rithikaa EllangovanMilford$216
- Ripudaman HundalNewark$370K
- Francisco PadillaSeaford$22K
- Reetu SinghLewes$9K
- Joanna KhatibMillsboro$7K
- Chitra ChoudharyDover$5K
- Ahmad ElayyanMillsboro$4K
- Sheetal BulchandaniNewark$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.